• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

东亚经皮冠状动脉介入治疗药物洗脱支架后高血小板反应性的中期预后意义中的性别差异:来自 PTRG-DES(冠心病药物洗脱支架治疗患者血小板功能和基因型相关长期预后)联盟的结果。

Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents in East Asian Patients: Results From the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) Consortium.

机构信息

Division of Cardiology, Department of Internal Medicine Kosin University College of Medicine Busan South Korea.

Division of Cardiology, Department of Internal Medicine Kangwon National University School of Medicine Chuncheon South Korea.

出版信息

J Am Heart Assoc. 2023 May 2;12(9):e027804. doi: 10.1161/JAHA.122.027804. Epub 2023 Apr 29.

DOI:10.1161/JAHA.122.027804
PMID:37119080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10227230/
Abstract

Background Although high platelet reactivity (HPR) on clopidogrel is associated with higher ischemic events and lower bleeding events in patients who have undergone percutaneous coronary intervention with drug-eluting stents, the differential risk of HPR in East Asian women versus men is unknown. Methods and Results We compared 11 714 patients enrolled in the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) Consortium according to sex and the presence/absence of HPR on clopidogrel (defined as ≥252 P2Y12 reactivity units). The primary study end point was major adverse cardiac and cerebrovascular events (MACCEs; comprising all-cause mortality, myocardial infarction, cerebrovascular accident, and stent thrombosis). HPR was more common in women (46.7%) than in men (28.1%). In propensity-adjusted models, HPR was an independent predictor of MACCEs (men with HPR: hazard ratio [HR], 1.60 [95% CI, 1.20-2.12]; women with HPR: HR, 0.99 [95% CI, 0.69-1.42]) and all-cause mortality (men with HPR: HR, 1.61 [95% CI, 1.07-2.44]; women with HPR: HR, 0.92 [95% CI, 0.57-1.50]) in men, although those associations were insignificant among women. In addition, a significant interaction between sex was noted in the associations between HPR and MACCE (=0.013) or all-cause mortality (=0.025). Conclusions In this study, HPR was a differential risk factor for 1-year MACCEs and all-cause mortality in women and men. And it was an independent predictor of 1-year MACCEs and all-cause mortality in men but not in women. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04734028. Registered July 9, 2003, https://clinicaltrials.gov/ct2/show/NCT04734028.

摘要

背景

尽管在接受药物洗脱支架经皮冠状动脉介入治疗的患者中,氯吡格雷的高血小板反应性(HPR)与更高的缺血事件和更低的出血事件相关,但东亚女性与男性之间 HPR 的差异风险尚不清楚。

方法和结果

我们根据性别和氯吡格雷 HPR(定义为≥252 P2Y12 反应单位)的存在/不存在,比较了参与 PTRG-DES(冠心病患者药物洗脱支架治疗后的血小板功能和基因型相关长期预后)研究联盟的 11714 名患者。主要研究终点是主要不良心脏和脑血管事件(MACCEs;包括全因死亡率、心肌梗死、脑血管意外和支架血栓形成)。HPR 在女性(46.7%)中比男性(28.1%)更为常见。在倾向调整模型中,HPR 是 MACCEs 的独立预测因子(男性 HPR:风险比[HR],1.60 [95%CI,1.20-2.12];女性 HPR:HR,0.99 [95%CI,0.69-1.42])和全因死亡率(男性 HPR:HR,1.61 [95%CI,1.07-2.44];女性 HPR:HR,0.92 [95%CI,0.57-1.50]),尽管在女性中这些关联无统计学意义。此外,在 HPR 与 MACCE(=0.013)或全因死亡率(=0.025)之间的关联中,观察到性别之间存在显著的交互作用。

结论

在这项研究中,HPR 是女性和男性 1 年 MACCEs 和全因死亡率的差异危险因素。并且它是男性而非女性 1 年 MACCEs 和全因死亡率的独立预测因子。

注册网址

https://www.clinicaltrials.gov;唯一标识符:NCT04734028。注册时间 2003 年 7 月 9 日,https://clinicaltrials.gov/ct2/show/NCT04734028。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/11d45508e3bd/JAH3-12-e027804-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/eed183849928/JAH3-12-e027804-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/eb7f7aa4fbc7/JAH3-12-e027804-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/1cea8527b3c8/JAH3-12-e027804-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/11d45508e3bd/JAH3-12-e027804-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/eed183849928/JAH3-12-e027804-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/eb7f7aa4fbc7/JAH3-12-e027804-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/1cea8527b3c8/JAH3-12-e027804-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0459/10227230/11d45508e3bd/JAH3-12-e027804-g001.jpg

相似文献

1
Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents in East Asian Patients: Results From the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) Consortium.东亚经皮冠状动脉介入治疗药物洗脱支架后高血小板反应性的中期预后意义中的性别差异:来自 PTRG-DES(冠心病药物洗脱支架治疗患者血小板功能和基因型相关长期预后)联盟的结果。
J Am Heart Assoc. 2023 May 2;12(9):e027804. doi: 10.1161/JAHA.122.027804. Epub 2023 Apr 29.
2
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).药物洗脱支架经皮冠状动脉介入治疗后高血小板反应性临床影响的性别差异:ADAPT-DES研究(药物洗脱支架双重抗血小板治疗评估)结果
Circ Cardiovasc Interv. 2017 Feb;10(2). doi: 10.1161/CIRCINTERVENTIONS.116.003577.
3
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).外周动脉疾病患者冠状动脉植入药物洗脱支架后的血小板反应性及临床结局:来自ADAPT-DES研究(药物洗脱支架双重抗血小板治疗评估)的分析
Circ Cardiovasc Interv. 2017 Mar;10(3). doi: 10.1161/CIRCINTERVENTIONS.116.004904.
4
Prognostic Implication of Platelet Reactivity According to Left Ventricular Systolic Dysfunction Status in Patients Treated With Drug-Eluting Stent Implantation: Analysis of the PTRG-DES Consortium.接受药物洗脱支架置入术治疗的患者中根据左心室收缩功能障碍状态评估血小板反应性的预后意义:PTRG-DES 联盟分析。
J Korean Med Sci. 2024 Jan 22;39(3):e27. doi: 10.3346/jkms.2024.39.e27.
5
Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium.糖尿病状态对药物洗脱支架置入后血小板反应性和临床结局的影响:来自 PTRG-DES 联盟的结果。
Cardiovasc Diabetol. 2023 Sep 7;22(1):245. doi: 10.1186/s12933-023-01976-4.
6
Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.氯吡格雷治疗下高血小板反应性与药物洗脱支架植入术后长期临床结局的关系(PAINT-DES):一项前瞻性、倾向评分匹配队列研究
BMC Cardiovasc Disord. 2018 May 24;18(1):103. doi: 10.1186/s12872-018-0841-1.
7
On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES.治疗中的血小板反应性与糖尿病患者的缺血结局:ADAPT-DES 的两年结果。
J Am Heart Assoc. 2023 Jan 3;12(1):e026482. doi: 10.1161/JAHA.122.026482. Epub 2022 Dec 24.
8
Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study.吸烟对经皮冠状动脉介入治疗后血小板反应性和临床结局的影响:ADAPT-DES 研究的结果。
Circ Cardiovasc Interv. 2019 Nov;12(11):e007982. doi: 10.1161/CIRCINTERVENTIONS.119.007982. Epub 2019 Nov 1.
9
Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.血小板功能检测调整抗血小板治疗失败的原因:来自 ARCTIC 研究的药效学见解。
Circ Cardiovasc Interv. 2019 Nov;12(11):e007749. doi: 10.1161/CIRCINTERVENTIONS.118.007749. Epub 2019 Nov 7.
10
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.经皮冠状动脉介入治疗术后血小板反应性与缺血性卒中风险:ADAPT-DES 研究。
JACC Cardiovasc Interv. 2018 Jul 9;11(13):1277-1286. doi: 10.1016/j.jcin.2018.01.263. Epub 2018 Jun 13.

本文引用的文献

1
Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium.药物洗脱支架置入后血小板反应性与临床结局:PTRG-DES 联盟研究结果。
JACC Cardiovasc Interv. 2022 Nov 28;15(22):2253-2265. doi: 10.1016/j.jcin.2022.09.007.
2
Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium.东亚患者 DES 植入后的血小板功能和基因型:PTRG-DES 联盟的原理和特征。
Yonsei Med J. 2022 May;63(5):413-421. doi: 10.3349/ymj.2022.63.5.413.
3
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.
东亚悖论:心血管疾病患者当前抗栓策略面临挑战的最新立场声明。
Thromb Haemost. 2021 Apr;121(4):422-432. doi: 10.1055/s-0040-1718729. Epub 2020 Nov 10.
4
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.更新的血小板功能和基因检测指导经皮冠状动脉介入治疗中 P2Y 受体抑制剂治疗的专家共识声明。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12.
5
Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease.稳定型冠状动脉疾病患者中,联合抗血小板治疗后血小板反应存在性别差异。
J Physiol Pharmacol. 2018 Aug;69(4). doi: 10.26402/jpp.2018.4.10. Epub 2018 Dec 9.
6
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.经皮冠状动脉介入治疗临床试验终点标准化定义:学术研究联合会-2 共识文件。
Eur Heart J. 2018 Jun 14;39(23):2192-2207. doi: 10.1093/eurheartj/ehy223.
7
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).药物洗脱支架经皮冠状动脉介入治疗后高血小板反应性临床影响的性别差异:ADAPT-DES研究(药物洗脱支架双重抗血小板治疗评估)结果
Circ Cardiovasc Interv. 2017 Feb;10(2). doi: 10.1161/CIRCINTERVENTIONS.116.003577.
8
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.抗血小板治疗致出血和支架血栓形成:经皮冠状动脉介入治疗后血小板反应性对危险分层作用的协作分析。
Eur Heart J. 2015 Jul 14;36(27):1762-71. doi: 10.1093/eurheartj/ehv104. Epub 2015 Apr 20.
9
Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.专家共识文件:世界心脏联合会专家共识声明:抗血小板治疗在东亚 ACS 或 PCI 患者中的应用。
Nat Rev Cardiol. 2014 Oct;11(10):597-606. doi: 10.1038/nrcardio.2014.104. Epub 2014 Aug 26.
10
Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial.基于性别的急性心肌梗死后经皮冠状动脉介入治疗中的出血和长期不良事件差异:来自 HORIZONS-AMI 试验的 3 年结果。
Catheter Cardiovasc Interv. 2015 Feb 15;85(3):359-68. doi: 10.1002/ccd.25630. Epub 2014 Sep 2.